- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03211273
Longitudinal Investigation of Cancer-related Fatigue (LIFT)
A Prospective, Observational Study to Investigate Longterm Courses, Patterns, Determinants and State of Treatment of Cancer-related Fatigue in Germany (LIFT)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The LIFT study aims to comprehensively investigate characteristics, determinants, and long-term course of fatigue. In addition, information shall be gained on the current state of fatigue treatment and care in Germany and on the needs of affected patients.
Data will be collected by mailed or online questionnaires at 6, 9, and 12 months as well as 2, 3, 4 and 5 years post-diagnosis from 2000 cancer patients. Besides questionnaires on socio-demographic, clinical and patient reported outcomes, saliva samples will be collected in order to gain new insights into biological mechanisms. Moreover, detailed data on screening, diagnosis and counseling as well as therapies offered and administered to reduce fatigue will be surveyed, as well as the patients' state of knowledge, perception and prevailing needs regarding fatigue. Tumor and cancer therapy data will be extracted from the Epidemiological Cancer Registry.
The results of the LIFT study aim to contribute to an improved, evidence-based and individualized treatment to avoid and ease cancer-related fatigue and will further promote patient-oriented offers and treatments.
Tipo de estudio
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- ≥ 18 years of age
- Diagnosed with a primary tumor of breast, ovarian, or colon cancer
- Time since first diagnosis is 4 - 6 months
- Having received or currently receiving at least one of the following treatments: surgery, chemotherapy, radiotherapy, hormone therapy, or immune therapy.
- Able to understand and follow the study protocol.
Exclusion Criteria:
• Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of diagnosis of the considered primary tumor
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Patient cohort
Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis.
No intervention.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Fatigue severity
Periodo de tiempo: from diagnosis to 1 year post-diagnosis
|
assessed by EORTC QLQ-FA12 (European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire)
|
from diagnosis to 1 year post-diagnosis
|
Impact of fatigue
Periodo de tiempo: from diagnosis to 1 year post-diagnosis
|
assessed by the Brief Fatigue Inventory (BFI)
|
from diagnosis to 1 year post-diagnosis
|
State of fatigue management
Periodo de tiempo: from diagnosis to 1 year post-diagnosis
|
Questionnaire assessing the adherence to the National Comprehensive Cancer Network (NCCN) guidelines regarding management of cancer-related fatigue
|
from diagnosis to 1 year post-diagnosis
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Quality of life functions and symptoms
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by EORTC QLQ-C30
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Sleep problems
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by Pittsburgh Sleep Quality Index (PSQI)
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Depression
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by Patient Health Questionnaire (PHQ-9)
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Body mass index
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
calculated from weight and height
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Total physical activity
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by a questionnaire regarding walking, cycling, and exercise behavior
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Diurnal cortisol rhythm
Periodo de tiempo: 1 year post-diagnosis
|
assessed in saliva
|
1 year post-diagnosis
|
Return to work
Periodo de tiempo: 6, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by a questions regarding occupational issues
|
6, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Hot flashes
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed only for women
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Anxiety
Periodo de tiempo: 6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
assessed by the Generalized Anxiety Disorder Questionnaire (GAD-7)
|
6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LIFT
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fatiga relacionada con el cáncer
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento